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Abstract
The innate immune response constitutes the first line of host defence that limits viral spread and plays an important role in
the activation of adaptive immune response. Viral components are recognized by specific host pathogen recognition
receptors triggering the activation of IRF3. IRF3, along with NF-kB, is a key regulator of IFN-b expression. Until now, the role
of IRF3 in the activation of the innate immune response during Varicella-Zoster Virus (VZV) infection has been poorly
studied. In this work, we demonstrated for the first time that VZV rapidly induces an atypical phosphorylation of IRF3 that is
inhibitory since it prevents subsequent IRF3 homodimerization and induction of target genes. Using a mutant virus unable
to express the viral kinase ORF47p, we demonstrated that (i) IRF3 slower-migrating form disappears; (ii) IRF3 is
phosphorylated on serine 396 again and recovers the ability to form homodimers; (iii) amounts of IRF3 target genes such as
IFN-b and ISG15 mRNA are greater than in cells infected with the wild-type virus; and (iv) IRF3 physically interacts with
ORF47p. These data led us to hypothesize that the viral kinase ORF47p is involved in the atypical phosphorylation of IRF3
during VZV infection, which prevents its homodimerization and subsequent induction of target genes such as IFN-b and
ISG15.
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Introduction
Innate immune response to viral infection involves the
recognition of viral components through pathogen recognition
receptors (PRRs) and the subsequent induction of type I IFNs
(IFN-a/b) that can trigger the expression of antiviral proteins.
Host PRRs recognize pathogen-associated molecular patterns
(PAMPs) such as viral nucleic acids [1,2]. PRRs comprise
membrane-associated receptors such as Toll-like receptors (TLRs)
and cytosolic receptors including RIG-I-Like Receptors (RLRs)
and Nucleotide-binding Oligomerization Domain (NOD)-Like
Receptors (NLRs) (for review [3]). More recently two new
cytosolic receptors have been identified: the DNA-dependent
Activator of IRFs (DAI), recognizing both microbial and host
DNA [4,5] and AIM2 (Absent in Melanoma 2) another DNA
sensor [6,7]. TLRs, RLRs and DAI are involved in viral detection
and lead to the activation of several transcription factors including
NF-kB, AP-1 and Interferon Regulatory Factor 3 (IRF3) that
cooperate to induce the expression of IFN-b. In turn, the newly
synthesized IFN-b, which is considered as the hallmark of the
antiviral response, induces the expression of Interferon-Stimulated
Genes (ISGs) encoding proteins such as 29-59 oligoadenylate
synthase (OAS), dsRNA-dependent protein kinase R (PKR) and
Interferon-Stimulated Gene 15 and 56 (ISG15 and ISG56) that
are responsible for the establishment of an antiviral state in
infected cells as well as in neighbouring non-infected cells [2,8,9].
By contrast to these PRRs, AIM2 induces the activation of the
inflammasome, leading to the maturation of pro-IL-1b in mature
IL-1b [4,7,10,11].
In resting cells, IRF3 is present in a latent conformation in the
cytoplasm. Upon viral infection, IRF3 is hyperphosphorylated on
multiple serine and threonine residues located at the C-terminus
[12,13,14]. Once phosphorylated, IRF3 homodimerizes and
translocates into the nucleus where it associates with the co-
activators CBP/p300 and activates the transcription of IFN-b in
collaboration with NF-kB and AP-1 [13]. It has previously been
demonstrated that the phosphorylation at the C-terminal domain
of IRF3 is mediated by the two non-canonical IkB kinase (IKK)-
related kinases IKK-e and TBK1 [15,16,17], activated in response
to the engagement of a PRR.
Varicella-Zoster Virus (VZV) is a human DNA virus belonging
to the alphaherpesvirus subfamily. VZV is a neurotropic virus that
causes two well-known pathologies: varicella (chicken pox) and
herpes zoster (shingles). Varicella results from primary infection
and is a common highly contagious childhood illness, associated
with fever and generalized vesicular rashes [18]. Following the
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migrates along neuronal cell axon to reach dorsal root ganglia
where it establishes a lifelong latent infection [19]. Reactivation
from latency, due to a weakness of the immune system, leads to
herpes zoster.
Varicella-Zoster Virus encodes two serine-threonine protein
kinases highly conserved among herpesviruses, namely ORF47
protein (ORF47p) and ORF66 protein (ORF66p), both present in
VZV virion. Heineman and colleagues previously showed that
these two viral kinases are dispensable for viral replication in cell
culture whereas others showed that they are essential for T cell
tropism [20,21,22,23,24]. Moreover, ORF47p is essential for VZV
replication in immature dendritic cells (DCs) but not in mature
DCs [23]. ORF47p, which is homologous to HSV-1 UL13,
hCMV UL97 and EBV BFLF4 protein kinases [25,26], recognizes
a consensus sequence similar to that of cellular casein kinase II
(CKII) [27]. It has been published that ORF47p autopho-
sphorylates in vitro and phosphorylates several viral proteins such
as the major VZV transactivator IE62 [28], the glycoprotein gE,
IE63 and the proteins encoded by ORF32 and ORF9
[29,30,31,32]. However no cellular target has been identified so
far.
On the contrary to ORF47p, that possesses homologs within a-,
b- and c-herpesvirus subfamilies, ORF66p is specific to the a-
herpesvirus subfamily and is homologous to HSV-1 US3 protein
kinase. Eisfeld and colleagues previously showed that VZV
ORF66p interacts with and phosphorylates the transcriptional
regulatory protein IE62, affecting its subcellular distribution
[33,34]. ORF66p has been shown to protect VZV-infected cells
from apoptosis by inhibiting Caspase 3 activation and to block
IFN-c-mediated STAT1 phosphorylation, leading to a decrease of
MHCI expression at the surface of VZV-infected cells [20,35].
Because IRF3 plays a major role in the type I IFN response to
viral infection, many viruses have developed different strategies to
subvert the host immune response by targeting this pathway. For
example, Herpes simplex virus (HSV), Human cytomegalovirus
(HCMV) and Epstein-Barr virus (EBV) encode proteins that
interfere with the IRF3 pathway [36,37,38,39,40]. The activation
of IRF3 in the context of VZV infection has been poorly studied
although Sen and co-workers recently showed that the VZV
immediate early protein IE62 inhibits its phosphorylation [41]. In
the present study, we examined the activation of IRF3 in response
to VZV and particularly the influence of the viral kinases encoded
by the ORFs 47 and 66 on its activation. We showed that
ORF47p but not ORR66p is involved in an atypical phosphor-
ylation of IRF3 that is inhibitory since it prevents IRF3
homodimerization. Furthermore, we observed that mRNA
amounts of two IRF3-dependent genes, IFN-b and ISG15, are
increased in cells infected with a mutant virus unable to express
the ORF47p (VZV ROka47S) compared to the wild-type (WT)
virus. We also demonstrated that ORF47p interacts with IRF3.
Based on these data, we hypothesized that VZV, through its kinase
ORF47p, targets the IRF3 pathway. Therefore the viral kinase
encoded by the ORF47 could play a role in mechanisms involved
in immune evasion following infection with VZV.
Results
IRF3 is phosphorylated during VZV infection
Since IRF3 is a transcription factor playing a central role in the
antiviral response, we decided to investigate whether IRF3 can be
activated upon VZV infection. In resting cells IRF3 is present as
two forms: form I and form II, corresponding respectively to the
non-phosphorylated and the basally phosphorylated form of IRF3.
These two forms appear as a doublet in SDS-PAGE. In general,
viral-mediated phosphorylation of IRF3 occurs within the C-
terminal domain on Ser385 and Ser386 residues as well as on the
serine/threonine cluster located between amino acids 396 and 405
[42]. This hyperphosphorylation, in the context of an infection
with the Sendai Virus, leads to the appearance of the forms III and
IV that migrate more slowly on SDS-PAGE and can thus be
discriminated from the forms I and II [14,43,44]. In the present
study, we evaluated the ability of VZV infection to induce the
appearance of such hyperphosphorylated forms of IRF3.
To analyze the phosphorylation of IRF3 in response to VZV
infection, HEK-293 cells were either mock- or VZV-infected and
collected various times post-infection. Total cell extracts were
resolved by SDS-PAGE. In mock-infected cells, IRF3 appears as a
doublet corresponding to the non-phosphorylated form (I) and the
basally phosphorylated form (II) (Figure 1A, lanes 1–4). In VZV-
infected cells a slower-migrating form of IRF3 appears as soon as
4 hours post-infection (hpi) (Fig. 1A, lane 5) and accumulates over
time, being still present at 32 hpi (Figure 1A, lane 8). Western
Blotting against the viral immediate-early protein IE63 was used to
control the viral infection.
To verify whether the slower-migrating form of IRF3, which
appears upon VZV infection, was effectively due to phosphory-
lation, total cell extracts both from mock- and VZV-infected cells
were treated or not with l-phosphatase during 45 min at 30uC. As
expected, treatment of mock-infected cells with l-phosphatase
induces the disappearance of the form II compared to the
untreated mock-infected cells (Figure 1B, lanes 1 & 2). In VZV-
infected cells untreated with the enzyme, IRF3 appears up-shifted
compared to untreated mock-infected cells (Figure 1B, lanes 1 & 3)
and the treatment of infected cells with the l-phosphatase totally
brings down the slower-migrating form of IRF3 compared to
untreated infected cells (Figure 1B, lanes 3 & 4). This result shows
that the up-shift of IRF3 appearing upon VZV infection is caused
by phosphorylation.
It has been previously demonstrated that the two non-canonical
IkB kinase homologs, namely IkB kinase-e (IKK-e or IKKi) and
TANK-binding kinase-1 (TBK1), are involved in the C-terminal
phosphorylation of IRF3 upon dsRNA stimulation or viral
infection [15,16]. Since we have shown that IRF3 is phosphor-
ylated in response to VZV, we wondered whether TBK1 was
involved in VZV-mediated phosphorylation of IRF3. To answer
this question, we have performed an in vitro Kinase Assay using
TBK1 immunoprecipitated from HEK-293 cells infected or not
with VZV and GST-IRF3 bearing the C-terminus of IRF3 as
substrate. Raw macrophages treated with LPS were used as
positive control (Figure 1C, upper panel, lane 2). Surprisingly, the
TBK1 immunoprecipitated from VZV-infected cells is not able to
phosphorylate the GST-IRF3 (Figure 1C, upper panel, lanes 7–9)
whereas, in corresponding inputs, IRF3 slower-migrating form
(referred to as P-IRF3 in the figure) is detectable (Figure 1C, lower
panel, lanes 7–9). Since TBK1 is known to phosphorylate the
serine 396 residue [16], TBK1 in vitro kinase assay result was
confirmed by Western Blotting using an antibody that specifically
recognizes the IRF3 phosphorylated on serine 396. According to
the absence of TBK1 activation, no IRF3 phosphorylated on
serine 396 has been detected in VZV-infected cells (data not
shown). Furthermore, we demonstrated that, in cells in which
TBK1 was knocked-down by specific siRNA, IRF3 is still
phosphorylated and up-shifted in response to VZV infection
(Figure 1D, lanes 7–9). The efficiency of TBK1 siRNA on the
inhibition of the IRF3 pathway activation has been verified by
analyzing the expression of IFN-b mRNA expression by semi-
quantitative RT-PCR (data not shown). Collectively, our data
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PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16870Figure 1. IRF3 is phosphorylated during VZV infection and then is unable to homodimerize. (A) HEK-293 cells were mock-infected or
infected with the WT VZV during the indicated periods of time. Total cell lysates were harvested, resolved by SDS-PAGE and immunoblotted with
specific antibodies against IRF3 and the viral protein IE63. (B) HEK-293 cells were mock-infected or infected with the WT VZV for 24 hours. Total cell
lysates were performed, treated or not with the l-phosphatase and then resolved by SDS-PAGE and immunoblotted with specific antibodies against
IRF3 and IE63. (C) Raw 264.7 macrophages were stimulated or not with LPS for 60 min. HEK-293 cells were mock-infected or infected with the WT VZV
during the indicated periods of time. Total cell extracts were performed and TBK1 was immunoprecipitated from these lysates with a specific
antibody. The Immunocomplexes were subjected to an in vitro kinase assay in the presence of radiolabelled ATP and the substrate GST-IRF3 bearing
the Carboxy- end of IRF3. Reactional mixes were then resolved by SDS-PAGE and TBK1 immunoprecipitation efficiency was analyzed by Western
Blotting. Inputs were also resolved by SDS-PAGE and Western Blottings against TBK1, IE63 and IRF3 were performed (lower panel). (D) HEK-293 cells
were transfected or not with 100 pmol of siRNAs directed against TBK1 or Firefly luciferase which was used as negative control. Cells were then non-
infected, mock-infected or infected with the WT VZV and 24 hours later cells were harvested. IRF3 up-shift was monitored by SDS-PAGE. TBK1
knockdown was confirmed by Western Blot analysis using a specific antibody against TBK1. Specific antibodies against IE63 and b-actin were also
used as control for infectivity and loading, respectively. (E) HEK-293 cells stably expressing TLR3 were stimulated or not with Poly (I:C) for 90 min. HEK-
293 cells were mock-infected or infected with the WT VZV during the indicated periods of time. Total cell extracts were performed and IRF3
homodimerization was analyzed by native gel electrophoresis.
doi:10.1371/journal.pone.0016870.g001
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require TBK1 kinase activity. Therefore, we concluded that VZV
induces the phosphorylation of IRF3 in a manner that appears to
be TBK1-independent and we referred the VZV-mediated
phosphorylation of IRF3 to as an atypical phosphorylation which
is indicated as P-IRF3 in the figures. This observation also led us
to hypothesize that this atypical phosphorylation may interfere
with IRF3 activation.
C-terminal phosphorylation of IRF3 is a critical step for its
activation since it allows its homodimerization and nuclear
translocation. Since VZV infection leads to a TBK1-independent
phosphorylation of IRF3, we wondered whether the VZV-
mediated phosphorylation of IRF3 permits its homodimerization.
HEK-293 cells were either mock-infected or VZV-infected and
examined various times post-infection. IRF3 homodimerization
was monitored by native PAGE as described previously [45].
HEK-293-TLR3 challenged with Poly (I:C) for 90 min were used
as positive control (Figure 1E, lane 2). IRF3 homodimerization
was observed neither in mock-infected cells (Figure 1E, lanes 4–7)
nor in VZV-infected cells (Figure 1E, lanes 8–11). Taken together,
these data suggest that VZV rapidly induces an atypical
phosphorylation of IRF3 that is a non-activating phosphorylation
since it does not allow IRF3 to homodimerize. Based on this, we
suggest that the VZV-mediated phosphorylation of IRF3, which
leads to its up-shift in SDS-PAGE, does not correspond to the
activated hyperphosphorylated forms III and IV that are observed,
for example, during an infection with the Sendai Virus [44].
The VZV viral kinase encoded by the VZV ORF47 but not
ORF66 is involved in the atypical phosphorylation of IRF3
VZV expresses two kinases encoded by the ORF47 and
ORF66. Some herpesviral kinases were reported to interfere with
the activation of IRF3. For example, EBV is responsible for an
inhibitory phosphorylation of IRF3 [40]. Therefore, we attempted
to elucidate whether VZV kinases were implicated in the atypical
phosphorylation of IRF3 observed following VZV infection. To
answer this question, two mutant viruses unable to express either
ORF47 (ROka47S) or ORF66 (ROka66S) proteins were used
[21,22]. HEK-293 cells were mock-infected or infected with the
WT VZV, the VZV ROka47S and the VZV ROka66S. Cells
were harvested at the indicated periods of time, total cell extracts
were performed and IRF3 up-shift was assessed by SDS-PAGE. As
already shown above, IRF3 is not up-shifted in mock-infected cells
(Figure 2A, lanes 1–3) whereas WT VZV rapidly leads to the
appearance of the IRF3 phosphorylated form (Figure 2A, lanes 4–
6). Surprisingly, IRF3 is not up-shifted when cells are infected with
the mutant ROka47S (Figure 2A, lanes 7–9) while phosphorylated
form of IRF3 is still observed in cells infected with the mutant
ROka66S (Figure 2A, lanes 10–12) as observed with the WT virus.
This result indicates that the viral kinase ORF47p but not
ORF66p is responsible for the appearance of the slower-migrating
form of IRF3 during VZV infection.
To confirm the relevance of the role of ORF47p in the
phosphorylation of IRF3 during VZV infection, the phosphory-
lation of IRF3 was evaluated in human primary mature myeloid
dendritic cells (mDCs) infected with the different viruses. mDCs
were prepared from human peripheral blood and infected with the
WT VZV or with the two mutant viruses (ROka47S and
ROka66S). Eight and 24 hours post-infection, mDCs were
collected, total cell extracts were performed and IRF3 up-shift
was analyzed by SDS-PAGE. IRF3 is not up-shifted in mock-
infected mDCs (Figure 2B, lanes 1 & 2) while infection with the
WT VZV leads to the appearance of an IRF3 slower-migrating
form (Figure 2B, lanes 3 & 4). As expected, IRF3 is no more up-
shifted in mDCs infected with the mutant VZV ROka47S
(Figure 2B, lanes 5 & 6) while it is still up-shifted in mDCs
infected with the mutant VZV ROka66S (Figure 2B, lanes 7 & 8).
The ability of the DCs to support the replication was verified by
analysis of VZV proteins from the three classes of genes, namely
IE63, ORF29p and gE (Figure 2B, lower panels). This result
confirms the observations in HEK-293 cells, highlighting that
ORF47p is involved in the atypical phosphorylation of IRF3
during VZV infection in primary cells. Taken together, these data
provide evidences that the viral kinase ORF47p, but not ORF66p,
plays an important role in the phosphorylation of IRF3 following
infection with VZV. Our experiments were then focused on the
effects of the viral kinase ORF47p rather than ORF66p on the
activation of IRF3 during VZV infection.
VZV ROka47S and ROka66S are derived from the VZV
vaccine strain ROka. Since we established comparisons between
the WT VZV, the vaccine ROka47S and ROka66S, we have
verified, by SDS-PAGE, that both the WT and the vaccine strains
behave the same in term of IRF3 phosphorylation (data not
shown).
Expression of exogenous ORF47p restored the up-shift of
IRF3 in cells infected with the mutant virus ROka47S
To objectivate in another way the role of the viral kinase
ORF47p in the atypical phosphorylation of IRF3 during VZV
infection, we decided to rescue the expression of ORF47p in
HEK-293 cells infected or not with the mutant VZV ROka47S.
HEK-293 cells were transfected or not with HA-ORF47
expressing vector. Twenty four hours later, cells were mock-
infected or infected with either the WT VZV or the mutant VZV
ROka47S for 24 hours. Cells were then harvested and total cell
lysates were performed. IRF3 up-shift was monitored by SDS-
PAGE. Infection with the WT VZV leads to the up-shift of IRF3
(Figure 3, lane 2) whereas no up-shift is observed in cells infected
with VZV ROka47S (Figure 3, lane 3). The restoration of
ORF47p expression in cells infected with VZV ROka47S leads to
a recovery of the shift showing a migration profile similar to the
one observed in cells infected with the WT VZV (Figure 3, lanes 2
& 6). Importantly, the ORF47p expression in mock-infected cells
does not induce the up-shift of IRF3 (Figure 3, lane 4) suggesting
that, alone, ORF47p is unable to induce the phosphorylated form
of IRF3 that is up-shifted in SDS-PAGE.
In absence of ORF47p expression, the osphorylation of
IRF3 on serine 396 is restored and IRF3 can
homodimerizeph
As already mentioned above, TBK1 was previously reported to
phosphorylate the C-terminal cluster of IRF3 that leads to its
homodimerization and its subsequent nuclear translocation [15].
The C-terminal cluster that is phosphorylated by TBK1 comprises
several serine and threonine residues including the serine 396
which phosphorylation is a prerequisite for IRF3 homodimeriza-
tion [12,48].
As demonstrated above, VZV induces an atypical phosphory-
lation of IRF3 that is TBK1-independent and is a non-activating
phosphorylation depending on the presence of the viral kinase
ORF47p. Based on this, we wondered whether the phosphoryla-
tion of IRF3 on serine 396 could be induced in cells infected with a
mutant virus unable to express the viral kinase ORF47p. HEK-
293 cells were mock-infected, infected with either the WT VZV or
the mutant VZV ROka47S. HEK-293 cells stably expressing
TLR3 treated with Poly (I:C) were used as a positive control.
Cytoplasmic and nuclear extracts were harvested at the indicated
VZV ORF47 Kinase Interferes with IRF3 Activation
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Blotting against IRF3 phosphorylated on serine 396 was
performed using a phosphospecific antibody (Figure 4A). As
expected, Poly (I:C) induces the phosphorylation of IRF3 on serine
396 (Figure 4A, upper panel, lane 2) whereas no phosphorylation
on this residue is detected neither in mock-infected cells (Figure A4,
Figure 2. The VZV kinase ORF47p but not ORF66p is involved in the phosphorylation of IRF3. (A) HEK-293 cells were mock-infected or
infected with the WT VZV and the two mutant viruses, namely VZV ROka47S and VZV ROka66S during the indicated periods of time. Total cell extracts
were performed and IRF3 up-shift was monitored by SDS-PAGE. The membrane was immunoblotted with specific antibodies against IRF3, HSP60 and
IE63. HSP60 and IE63 were used as control for loading and infectivity, respectively. (B) Mature mDCs were prepared as described in the Material and
Methods and co-cultured with either non-infected MeWo cells or with MeWo cells infected either with the WT VZV, the mutant VZV Roka47S or
Roka66S for 24 hours. Non-adherent mDCS were then collected and placed into fresh 6-well plates. Cells were harvested after supplemental 8 and
24 hours and total cell extracts were performed. The up-shift of IRF3 was monitored by SDS-PAGE. The membrane was immunoblotted with specific
antibodies against IRF3 and HSP60. HSP60 was used as control for loading. Following viral proteins were also detected with specific antibodies: IE63,
ORF29p and gE.
doi:10.1371/journal.pone.0016870.g002
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upper panel, lanes 5 & 6) while the phosphorylation of IRF3 on
serine 396 seems to be recovered in cells infected with the mutant
VZV ROka47S (Figure 4A, upper panel, lane 8). Western Blotting
against an exclusively nuclear protein 53BP1 was used as a control
for nuclear proteins (Figure 4A, lower panel). Corresponding
cytoplasmic extracts were also resolved in SDS-PAGE to verify the
IRF3 up-shift (Figure 4A, lower panel). As demonstrated above,
IRF3 is up-shifted in cells infected with the WT VZV (Figure 4A,
lower panel, lanes 5 & 6) whereas no up-shift is detected in cells
infected with the mutant VZV ROka47S (Figure 4A, lower panel,
lanes 7 & 8). Western Blotting against the viral protein IE63 was
also performed to control cell infectivity.
Although IRF3 is phosphorylated on serine 396 in response to
Poly (I:C) treatment as well as in cells infected with the mutant
VZV ROka47S (Figure 4A, upper panel, lanes 2 & 8) it is not up-
shifted in SDS-PAGE (Figure 4A, lower panel, lanes 2 & 8). This
result demonstrates that the phosphorylation of IRF3 on serine
396 that leads to its activation is not necessarily accompanied with
the appearance, in SDS-PAGE, of up-shifted forms of IRF3 as it
can be observed, for example, during Sendai Virus infection [44].
Since phosphorylation on serine 396 seems to be restored in
cells infected with the mutant VZV ROka47S, we wondered
whether IRF3 could also homodimerize in absence of ORF47p
expression. HEK-293 cells were mock-infected or infected with
either the WT VZV or the mutant VZV ROka47S. Cells were
harvested at various times post-infection and IRF3 homodimer-
ization was monitored by native PAGE. Poly (I:C) treatment,
known to induce the homodimerization of IRF3, was used as a
positive control in HEK-293-TLR3 (Figure 4B, lane 1). As
expected, IRF3 does not homodimerize in VZV-infected cells
(Figure 4B, lanes 3-5) but interestingly, IRF3 homodimers are
present in cells infected with the mutant VZV ROka47S
(Figure 4B, lanes 6-8). This result is in accordance with our
hypothesis that the viral kinase ORF47p interferes with the
activation of IRF3 during VZV infection. VZV, through its
ORF47p kinase, induces an atypical phosphorylation of IRF3 that
does not occur on serine 396 and prevents its homodimerization.
Altogether, our data suggest that the modified form of IRF3,
induced upon VZV infection that leads to its upshift in SDS-
PAGE, is indeed due to some phosphorylation of IRF3 but has to
be distinguished from the activated hyperphosphorylated forms III
and IV.
Figure 3. Expression of exogenous ORF47p restores the
phosphorylation of IRF3 in cells infected with VZV ROka47S.
HEK-293 cells were transfected or not with HA-ORF47 expressing vector.
24 hours later, cells were mock-infected or infected with either the WT
VZV or the mutant VZV ROka47S for another 24 hours. Total cell
extracts were performed, resolved by SDS-PAGE and immunoblotted
with specific antibodies against IRF3, HA-tag, IE63 and b-actin. Anti-HA
antibody was used to control the transfection efficiency. IE63 was used
as a control for infectivity while b-actin was used as a loading control.
doi:10.1371/journal.pone.0016870.g003
Figure 4. In absence of ORF47p expression, IRF3 is phosphor-
ylated on serine 396 and homodimerizes again. HEK-293 cells
stably expressing TLR3 were stimulated or not with Poly (I:C) for 90 min.
HEK-293 cells were mock-infected or infected with either the WT VZV or
the mutant VZV ROka47S during the indicated periods of time. (A)
Cytoplasmic and nuclear extracts were harvested. Nuclear proteins were
resolved by SDS-PAGE and immunoblotted with specific antibodies
against IRF3 phosphorylated on serine 396 and the nuclear protein
53BP1 while cytoplasmic proteins were used to perform Western
Blotting against IRF3 and the viral protein IE63 using specific antibodies.
(B) Total cell extracts were performed and IRF3 homodimerization was
analyzed by native gel electrophoresis. The membrane was then
immunoblotted with a specific antibody against IRF3.
doi:10.1371/journal.pone.0016870.g004
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infected with VZV ROka47S compared to WT VZV
Since IRF3 is able to form homodimers in response to VZV
infection when the viral kinase ORF47p is not expressed, we
wondered whether infection with the mutant VZV ROka47S leads
to an increase of IRF3-dependent gene expression compared to
the WT VZV infection. To answer this question, the expression of
two IRF3 target genes, namely IFN-b and ISG15 was analyzed by
qRT-PCR in HEK-293 cells stably expressing TLR3. HEK-293
cells stably expressing TLR3 were mock-infected or infected with
either the WT VZV or the mutant VZV ROka47S for 8 h. Cells
were harvested and total RNA were isolated and subjected to a
quantitative RT-PCR in presence of SYBR Green. As shown in
Figure 5A, infection with the WT VZV slightly increases the
expression of IFN-b whereas infection with VZV ROka47S leads
to a much higher expression of IFN-b mRNA. Similarly, the same
profile is observed with ISG15 mRNA (Figure 5B). Altogether,
these data revealed that, during infection with the WT VZV, the
viral kinase ORF47p is responsible for the decrease of IRF3-
dependent genes expression.
ORF47p interacts with IRF3
Next, we decided to determine, via co-immunoprecipitation, if
ORF47p and IRF3 can physically interact. HEK-293 cells were
transfected either with HA-tagged ORF47 (Figure 6, lanes 3 & 8)
or V5-tagged IRF3 (Figure 6, lanes 4 & 9) or co-transfected with
both plasmids (Figure 6, lanes 1, 2, 5, 6 & 7). Twenty four hours
later, cells were infected or not with VZV ROka47S for another
24 hours. Inputs and immune complexes were analyzed by
Western Blotting. Immunoprecipitation efficiency was checked
(Figure 6, lower panel, lanes 6–9) and a negative control without
antibody was performed (Figure 6, lane 5). We showed that, when
immunoprecipitated, IRF3 efficiently co-precipitates HA-ORF47
even in absence of viral infection (Figure 6, lanes 6 & 7). Similarly,
when immunoprecipitated, HA-ORF47p co-precipitates IRF3
(data not shown).
The viral kinase ORF47p is not responsible for the VZV-
mediated inhibition of NF-kB activation
Our data showed that VZV targets the activation of IRF3 by
inducing its phosphorylation that is dependent on the viral kinase
ORF47p. This phosphorylation inhibits IRF3 homodimerization
preventing the subsequent induction of target genes such as IFN-b
and ISG15, as demonstrated by qRT-PCR experiments. The
induction of IFN-b expression requires the cooperation between
IRF3 and NF-kB. We and others have recently demonstrated that
VZV interferes with the activation of NF-kB [49,50]. As shown
above, we observed that IFN-b expression is very low following
infection with VZV. Therefore, we wondered whether this low
level of expression was also due to an interference with the
activation of NF-kB and whether the activation of NF-kBi s
restored following infection with the mutant VZV ROka47S. In
order to investigate whether the viral kinase ORF47p is involved
in this VZV-mediated inhibition of NF-kB activation, the NF-kB
binding activity was examined by electrophoretic mobility shift
assay (EMSA). Raw macrophages were treated with LPS for one
hour and HEK-293 cells stably expressing TLR3 were left
untreated or treated with Poly (I:C) for 90 min. HEK-293 were
mock-infected or infected with either the WT VZV or the mutant
ROka47S. Cells were harvested at the indicated periods of time
and nuclear extracts were performed. Nuclear extracts were then
analyzed by electrophoretic mobility shift assay using a probe
carrying the kB consensus sequence of the HIV LTR promoter.
As shown in Figure 7A, treatment with LPS and Poly (I:C) induce
a NF-kB DNA binding on the probe (Figure 7A, lanes 1 & 3). As
expected, no binding is induced both in mock-infected cells
(Figure 7A, lanes 4 & 5) and in cells infected with the WT VZV
(Figure 7A, lanes 6 & 7). Furthermore, NF-kB DNA binding is not
restored in cells infected with the mutant VZV ROka47S
(Figure 7A, lanes 8 & 9). In order to confirm this result, the
expression of IkBa mRNA, a NF-kB inducible gene, was carried
out by qRT-PCR (Figure 7B). HEK-293 cells stably expressing
TLR3 were left untreated or treated with TNFa (500 U/ml) for
Figure 5. In absence of ORF47p expression, IRF3-dependent gene expression is increased. HEK-293 cells stably expressing TLR3 were
mock-infected or infected with either the WT VZV or the mutant VZV ROka47S for 8 hours. Total RNA were harvested and subjected to a Reverse
Transcription reaction. cDNA were subjected to a quantitative Real Time PCR in presence of SYBR Green. Primers directed to ifnb (A) and isg15 (B)
were used. RT-PCR was normalized using the 18S RNA expression level. Error bars indicate the standard deviation of the mean.
doi:10.1371/journal.pone.0016870.g005
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VZV or the mutant VZV ROka47S for 8 hours. Cells were
harvested and total RNA were isolated and subjected to a
quantitative RT-PCR. As shown in the Figure 7B, the treatment
with TNFa induces the expression of IkBa mRNA whereas the
amount of IkBa mRNA is not increased neither in cells infected
with the WT VZV nor in cells infected with the mutant VZV
ROka47S. Therefore, these data are in accordance with the
mobility shift assay experiment and collectively, they suggest that
the activation of NF-kB is not modulated by the viral kinase
ORF47p unlike IRF3. Thereby, these observations led us to
hypothesize that the viral kinase ORF47p only targets the IRF3
pathway to prevent subsequent induction of IFN-b.
Discussion
The innate immune response constitutes the first line of defence
and plays an important role in the detection of invading pathogens
therefore limiting the spread of infectious agents. The innate
immune response is characterized particularly by the activation of
IRF3 which plays a central role in the expression of IFN-b which
in turn, induces the expression of interferon stimulated genes
(ISGs) encoding proteins playing important roles in mounting an
antiviral response leading to the clearance of pathogens. Viruses
are considered as obligate parasites that use host machinery to
replicate. Therefore, viruses have developed mechanisms to
subvert host immune responses in order to increase viral spread.
Herpesviruses are characterized by the establishment of a lifelong
latency in host after primary infection. Thus, they developed
various strategies to evade and bypass host innate immune
responses. Indeed, it is well documented that Herpesviruses such
as Herpes simplex virus type 1 (HSV-1), human Cytomegalovirus
(hCMV) and Epstein-Barr virus (EBV) encode proteins that
interfere with host innate immune responses and more particularly
with the IRF3 pathway. For example, HSV-1 ICP0 and hCMV
IE86 were reported to interfere with IRF3 activation and/or IFN-
b expression [37,51,52]. In addition, some viral kinases were
recently reported to interfere with the IRF3 activation [40,46,47].
In this study, we have attempted to investigate whether VZV
interferes with the IRF3 pathway and whether the two VZV
kinases, ORF47p and ORF66p, are involved in this VZV-
mediated interference. The activation of IRF3 pathway during
VZV infection was carried out in HEK-293 cells and the main
results presented in this work can be summarized as follow: (i)
Infection with VZV induces a rapid and persistent phosphoryla-
tion of IRF3 that does not require TBK1 kinase activity; (ii) IRF3
does not homodimerize upon infection with VZV; (iii) The viral
kinase ORF47p but not ORF66p is involved in the VZV-mediated
phosphorylation of IRF3 in HEK-293 cell line but also in human
primary dendritic cells; (iv) When ORF47p expression is restored
in cells infected with the mutant ROka47S, IRF3 is up-shifted
again. (v) In absence of ORF47p expression, IRF3 phosphoryla-
tion on serine 396 and IRF3 homodimerization are restored
whereas NF-kB activation is not restored; (vi) IFN-b and ISG15
mRNA amounts are increased in absence of ORF47p expression;
(vii) Exogenous HA-ORF47p physically interacts with IRF3 in
transient transfection.
To be activated, IRF3 requires phosphorylation at key serine/
threonine residues located at the C-terminus of the protein.
Among these residues, serine 396 was identified as the minimal
phosphoacceptor site required for in vivo activation of IRF3 [12].
Since IRF3 is a transcription factor playing a central role in the
activation of innate immune response, viruses often inhibit its
activation and/or subsequent induction of target genes such as
IFN-b. Here, we showed for the first time that, following infection
with VZV, an IRF3 slower-migrating form appears as soon as
4 hours post-infection and accumulates over time. Morevover, we
highlighted that this slower-migrating form is caused by phos-
phorylation as shown by l-phosphatase treatment. TBK1 is
known to phosphorylate IRF3 at the C-terminus leading to its
homodimerization and its subsequent nuclear translocation
[15,16]. Here, we demonstrated, in an in vitro assay, that TBK1
is not activated in VZV-infected cells as, once immunoprecipitat-
ed, it is unable to phosphorylate the GST-IRF3 bearing the
Carboxy-end of the protein. This result was confirmed by Western
Blotting using an antibody that specifically recognizes the IRF3
phosphorylated on serine 396. Moreover, we showed, by using
specific siRNA against TBK1, that this cellular kinase does not
seem to be required for the VZV-dependent phosphorylation of
IRF3 since the partial depletion of TBK1 does not impact on the
up-shift observed. Therefore, we concluded that VZV induces the
phosphorylation of IRF3 in a manner that appears to be TBK1-
independent and we referred the VZV-mediated phosphorylation
of IRF3 to as an atypical phosphorylation. Furthermore, this
Figure 6. IRF3 physically interacts with ORF47p. HEK-293 cells were transfected either with HA-tagged ORF47 or V5-tagged IRF3 or co-
transfected with both plasmids. 24 hours later, cells were infected or not with the mutant VZV ROka47S for another 24 hours. Either IRF3 or HA-
ORF47 was immunoprecipitated from total extracts with anti-IRF3 and anti-HA antibodies. Inputs and immune complexes were then analyzed by
Western Blotting using specific antibodies against HA-tag and IRF3. A negative control without antibody was also performed.
doi:10.1371/journal.pone.0016870.g006
VZV ORF47 Kinase Interferes with IRF3 Activation
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e16870observation led to the hypothesis that this atypical phosphorylation
may interfere with IRF3 activation. We verified this hypothesis by
analyzing the homodimerization of IRF3 by native PAGE and
surprisingly, our result demonstrated that the VZV-induced
phosphorylation of IRF3 does not lead to the formation of IRF3
homodimers.
Altogether, our data led us to conclude that VZV infection
induces an atypical phosphorylation of IRF3, which leads to the
appearance of an up-shifted form in SDS-PAGE but not to the
homodimerization of the protein and which does not concern the
critical residue serine 396 and therefore has to be distinguished
from the activating hyperphosphorylation leading to the so-called
Figure 7. ORF47p is not responsible for the inhibition of NF-kB pathway during VZV infection. (A) Raw 264.7 macrophages were
stimulated with LPS for 60 min. HEK-293 cells stably expressing TLR3 were stimulated or not with Poly (I:C) for 90 min. HEK-293 cells were mock-
infected or infected with either the WT VZV or the mutant VZV ROka47S during the indicated periods of time. Various times post-infection, cells were
collected and nuclear extracts were performed. 5 mg of nuclear proteins were used to study the NF-kB binding activity by EMSA using a radiolabeled
probe carrying the NF-kB consensus sequence of HIV LTR promoter. (B) HEK-293 cells stably expressing TLR3 were stimulated or not with TNFa for
2 hours. Cells were mock-infected or infected with either the WT VZV or the mutant VZV ROka47S for 8 hours. Total RNA were harvested and
subjected to a Reverse Transcription reaction. cDNA were subjected to a quantitative Real Time PCR in presence of SYBR Green and primers directed
to ikba. RT-PCR was normalized using the 18S RNA expression level. Error bars indicate the standard deviation of the mean.
doi:10.1371/journal.pone.0016870.g007
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VZV is able to interfere with the activation of IRF3 following viral
infection. Indeed, infections with HSV-1 and hCMV rapidly
activate IRF3 following virus binding and entry [53,54,55].
However, these two herpesviruses encode proteins that antagonize
IRF3 activation and subsequent type I IFNs expression
[37,51,52,56,57,58]. On the contrary to HSV-1 and hCMV, our
data demonstrated that VZV rapidly prevents IRF3 from
homodimerization as soon as 4 hours post-infection and probably
does not require de novo synthesis of viral proteins. Therefore, we
hypothesized that one or several tegument proteins released into
the cytoplasm soon after viral entry could rapidly encounter IRF3
and induce its atypical phosphorylation preventing thereby its
homodimerization. VZV tegument proteins include the major
viral transactivator, IE62 as well as IE63, ORF9p and the two viral
kinases, namely ORF47p and ORF66p. Based on this, we decided
to analyze whether the two VZV kinases, namely ORF47p and
ORF66p are involved in the VZV-mediated phosphorylation of
IRF3. Using two mutant viruses unable to express either ORF47p
(ROka47S) or ORF66p (ROka66S), we demonstrated for the first
time that, during viral infection, the kinase ORF47p but not
ORF66p is involved in the VZV-mediated phosphorylation of
IRF3 since it is no more up-shifted in absence of ORF47p as
shown by Western Blotting. We have confirmed this finding in
human primary dendritic cells highlighting the relevance of
ORF47p in the phosphorylation of IRF3 following VZV infection.
Furthermore, by restoring the expression of ORF47p in cells
infected with the mutant VZV ROka47S, we showed that IRF3
recovers a migration profile similar to that observed in cells
infected with the WT virus. However, we observed that, alone,
ORF47p is unable to induce the up-shift of IRF3 suggesting that
ORF47p may need other VZV protein(s) to induce IRF3
phosphorylation during VZV infection.
Furthermore, we have shown that, in absence of ORF47p
expression, the phosphorylation of IRF3 on serine 396 is restored
and IRF3 can homodimerize again. So, it appears that the atypical
phosphorylation of IRF3, which depends on the viral kinase
ORF47p, prevents IRF3 classical phosphorylation on serine 396
and subsequent IRF3 homodimerization. Accordingly, we showed
that, in absence of ORF47p expression, mRNA amounts of two
IRF3 target genes, namely IFN-b and ISG15, are significantly
increased in cells infected with the mutant ROka47S compared to
cells infected with the WT VZV. Importantly, our data are in line
with those of Wang and colleagues showing that the EBV viral
kinase BGLF4, homologous to ORF47p, inhibits the activation of
IRF3 [40]. But, on the contrary to ORF47p, it was reported that
BGLF4-mediated phosphorylation of IRF3 does not prevent its
homodimerization and subsequent nuclear translocation. In
addition, other herpesviral kinases such as HSV-1 UL13 kinase
and the murine MHV-68 ORF36 kinase were reported to
interfere with type I IFNs expression and with IRF3 binding to
CBP/p300, respectively [46,47]. EBV BGLF4, HSV-1 UL13,
MHV-68 ORF36 and VZV ORF47p are homologous to each
other and are conserved kinases among Herpesviruses in both
human and mice [59] showing their importance in evasion of host
innate immune response as well as the relevance of ORF47p in the
inhibition of IRF3 activation during VZV infection. However, the
complete mechanism by which ORF47p induces the phosphor-
ylation of IRF3 is still to be investigated. Indeed, we do not know
whether ORF47p directly phosphorylates IRF3 and whether the
kinase activity of ORF47p is required for this function. We also do
not know the region of IRF3 that is targeted in the presence of
ORF47p. ORF47p has been previously reported to recognize a
consensus sequence similar to that of the cellular CKII [27] and
the in silico analysis of IRF3, using the Scansite software, reveals
the presence of four potential CKII-like sites in the N-terminal
region of IRF3. Therefore, we intend to investigate whether these
predicted sites are targeted by the ORF47p. Collectively, our data
suggest that VZV interferes with the activation of IRF3 through its
kinase ORF47p, which induces an atypical phosphorylation of
IRF3 that does not allow the classical phosphorylation on serine
396 and subsequent IRF3 homodimerization. Hence, infection
with the mutant virus unable to express the viral kinase ORF47p
results in the restoration of IRF3 serine 396 phosphorylation,
homodimerization and an enhanced expression of IRF3 target
genes such as IFN-b and ISG15.
Next, we showed, by co-immunoprecipitation in overexpressing
cells, that IRF3 physically interacts with ORF47p. As ORF47p,
alone, is able to interact with IRF3 but unable to induce its up-
shift, we can postulate that another VZV protein is needed to
allow IRF3 phosphorylation by ORF47p. This other VZV protein
should also be a tegument protein since VZV-mediated IRF3
phosphorylation happens very early after infection. Very recently,
Sen and co-workers demonstrated that the major VZV transacti-
vator, IE62, interferes with the C-terminal phosphorylation of
IRF3 thereby preventing IFN-b expression in absence of synthesis
of de novo viral proteins [41]. IE62, along with ORF47p, is a
tegument protein and both are consequently released in the
cytoplasm of host cell upon viral entry. Since IE62 has been
reported to be a substrate for the VZV kinase ORF47p [32], we
can postulate that IE62 is present in the complex composed of
IRF3 and ORF47p and could induce a conformational change
thereby permitting the ORF47p-mediated phosphorylation of
IRF3. We can also postulate that, in absence of the kinase
ORF47p, IE62 is not phosphorylated anymore and may prevent
the VZV-mediated inhibition of IRF3 as it was previously
suggested for HSV-1 UL13 kinase and its substrate, ICP0 [46].
Finally, it is possible that IE62 and ORF47p act at different levels
of the IRF3 pathway leading in fine to its inhibition.
The only common conclusion we can draw in comparison with
the work of Sen and co-workers is the inhibition of the IRF3
pathway following infection with VZV. One should notice that
Sen and colleagues showed that IE62 inhibits IRF3 phosphory-
lation only by transient transfection experiments using artificial
expression of TBK1, IRF3 and IE62, whereas our data have been
conducted in a more physiologically relevant context. Indeed, the
main experiments demonstrating that ORF47p interferes with the
activation of IRF3 were performed in the context of viral infection
using WT VZV, vaccine ROka and mutant strains. Moreover, the
activation of IRF3 was evaluated on the endogenous protein by
Western Blotting. As IE62 is a potent transactivator essential for
the viral replication, it is not easy to investigate its potential role in
the inhibition of IRF3 in VZV-infected cells. Nevertheless, as IE62
is a target of ORF47p, it would be interesting to explore the
possibility that they both play a role in the VZV-induced
inhibitory phosphorylation of IRF3.
As already mentioned above, we observed that VZV interferes
with the activation of IRF3 and the subsequent induction of two
IRF3-dependent genes, namely IFN-b and ISG15 through its
kinase ORF47p. We and other have previously shown that NF-kB
activation was inhibited during VZV infection [49,50]. Since IFN-
b expression is induced by the cooperation between IRF3 and NF-
kB, we wondered whether the decrease of IFN-b expression
during VZV infection was also due to an inhibition of NF-kB
activation. To answer this question, we investigated whether the
absence of ORF47p expression restores the activation of NF-kB
following infection with VZV. Our data showed that the activation
of NF-kB is not restored upon infection with the mutant virus that
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with the WT virus. Considering this finding, we suggest that the
decrease of IFN-b expression during VZV infection is due to an
ORF47p-mediated inhibition of IRF3 activation but not NF-kB.
Collectively, our data support a mechanism by which VZV
interferes with the activation of IRF3 and the subsequent induction
of the antiviral response, which is summarized in the Figure 8.
Through its kinase ORF47p, VZV induces an atypical phosphor-
ylation of IRF3 that prevents its homodimerization and subsequent
induction of target genes such as IFN-b and ISG15, thereby
interfering with the activation of an antiviral state in the host cell.
Materials and Methods
Cell culture
Human embryonic kidney-293 (HEK-293) cell line (#ACC305,
Deutsche Sammlung Von Mikroorganismen und Zellkulturen
(DSMZ), Germany), Human embryonic kidney-293 expressing
Toll-like receptor 3 (HEK-293-TLR3) cell line (#293-htlr3, Invivo-
Gen) and Raw 264.7 macrophages (#TIB-71; ATCC, USA) were
cultured in Dulbecco’s Modified Eagle’s medium (Lonza, Petit-
Rechain, Belgium) supplemented with 10% fetal bovine serum, 1%
glutamine and 1% non essential amino acids (GibcoH, Invitrogen).
Human melanoma cell line (MeWo) (#93082609; ECACC,
England) was cultured in Eagle’s minimal essential medium (Lonza)
supplemented with 10% fetal bovine serum and 1% glutamine.
VZV infection
The VZV wild-type NIK strain is a gift from Dr. Arjen F.
Nikkels. VZV ROka47S and VZV ROka66S were generated by
insertion of Stop codons in the ORF47 and ORF66 and obtained
form Jeffrey I. Cohen [21,22]. The VZV ROka vaccine strain was
obtained from Dr. Marvin Sommer [60]. Viruses were grown in
human melanoma MeWo cell line. HEK-293 cells were infected
with VZV by co-cultured with VZV-infected MeWo cells at a ratio
1 to 1, for 30 min at 37uC. The inoculum has been washed away
and HEK-293 cells were cultured in fresh medium and harvested
at various time points after infection.
Figure 8. Model of VZV-mediated interference with IRF3 activation. Upon VZV entry, the viral kinase ORF47p, which is part of the VZV
tegument, is released in the cytoplasm where it can encounter IRF3 and induce its atypical phosphorylation leading to an up-shift in the
electrophoretic mobility of IRF3. Our data demonstrated that VZV does not activate the cellular kinase TBK1 and that VZV ORF47p-mediated
phosphorylation of IRF3 does not occur on the classical serine 396. Furthermore, this atypical phosphorylation does not allow IRF3 homodimerization
and subsequent induction of target genes such as IFN-b and ISG15. Consequently, the phosphorylated forms of IRF3 engendered by VZV through its
ORF47 kinase, even if leading to an up-shift in SDS-PAGE, have to be distinguished from the hyperphosphorylated forms III and IV induced by other
viruses such as the Sendai Virus. In addition, we have shown, in cells infected with a mutant virus unable to express the viral kinase ORF47, that the
phosphorylation of IRF3 on serine 396 is restored. Hence, IRF3 homodimerizes again in cells infected with this ORF47 deficient virus. However, we
failed to detect an up-shift of IRF3 in SDS-PAGE in these infected cells. Surprisingly, IRF3 showed the same behaviour in response to Poly (I:C)
treatment suggesting that IRF3 phosphorylation on serine 396 and subsequent homodimerization are not necessarily accompanied with an up-shift
in SDS-PAGE as observed in the context of an infection with the Sendai Virus. This also suggests that another activated form of IRF3, different than
the forms III and IV, can exist. Until now, we still do not know whether ORF47p requires other viral proteins such as IE62 to mediate IRF3
phosphorylation following VZV infection. We also do not know whether this phosphorylation occurs at the C- or N-terminus of IRF3. Finally, we have
shown that VZV inhibits the activation of NF-kB and that this inhibition is independent on the viral kinase ORF47p. In conclusion, we propose a model
in which VZV interferes with the activation of IRF3 and subsequent induction of the antiviral response through its kinase ORF47p.
doi:10.1371/journal.pone.0016870.g008
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generation of mature Myeloid DCs
Human peripheral blood was obtained from the ‘‘Centre de
Transfusion Sanguine’’ (Croix Rouge de Lie `ge, Belgium). PBMCs were
isolated from buffy coat by density gradient sedimentation with
Lymphoprep
TM (Axis-Shield, Norway). CD14 positive monocytes
within PBMC were positively selected by incubating cells with
anti-CD14 microbeads (Miltenyi, Germany) and running through
a MS column (Miltenyi) in a magnetic field. The bound monocytes
were then washed away from the column and culture at 37uCi n
5% CO2 in RPMI1640 (Lonza) supplemented with 1% non
essential amino acids, 1% sodium pyruvate 1% glutamine, 1%
penicillin/streptomycin, 50 U/ml of IL-4 (Immunotools, Ger-
many) and 800 U/ml of Granulocyte-Macrophage-Colony-Stim-
ulating Factor (GM-CSF) (Immunotools, Germany). IL-4 and
GM-CSF were added to the culture medium every two days for 7
days. On day 8, immature myeloid DCs were then treated with
LPS (100 ng/ml) for 24 hours. On day 9, DCs phenotype was
determined using flow cytometry. The cells consisted of .90%
mature myeloid DCs as determined by their morphology and their
cell surface phenotype (i.e CD1a
+, CD80
+ and CD86
+).
Flow cytometry analyzes and antibodies
Monoclonal antibodies specific for human CD1a (clone NA1/34;
FITC conjugated), human CD14 (clone Tu ¨k4; RPE conjugated),
human HLA DR (clone AB3; FITC conjugated) were purchased
from Zebra Bioscience (Enschede, Netherlands). Monoclonal
antibody for human CD86 (clone 2331; APC conjugated) was
obtained from BD Pharmingen (Becton Dickinson, Erembodegem,
Belgium). Monoclonal antibody for human CD80 (PE conjugated)
was purchased from Immunosource (Halle-Zoersel, Belgium).
VZV infection of mature myeloid DCs
MeWo cells seeded in 6-well plates were infected or not with
VZV WT, VZV ROka47S and VZV ROka66S. 48 hours post-
infection (when cells showed ,80% of infectivity), 2610
5 mature
DCs were added to each well of VZV-infected MeWo cells in
RPMI supplemented with 1% non essential amino acids, 1%
sodium pyruvate, 1% glutamine and 1% penicillin/streptomycin.
After 24 h, the nonadherent DCs were removed and placed into
new 6-well plates and cultured for supplemental 8 and 24 h, before
being harvested as described previously [23].
Reagents
LPS (#L4391) and Polyinosinic–polycytidylic acid potassium
salt [poly (I:C)] (#P9582) were obtained from Sigma-Aldrich and
used at a concentration of 400 ng/ml and 50 mg/ml, respectively.
TNFa (#300-01A) was obtained from PeproTech EC (UK) and
used at a concentration of 500 U/ml.
Plasmids
ORF47-HA-tagged was kindly provided by Paul R. Kinching-
ton. To construct IRF3 in frame with V5 epitope, IRF3 gene was
amplified by PCR from the pEGFPC1-IRF3 (kindly provided by
Dr. Denis Gerlier) and cloned into the pCDNA3.1/V5-His-
TOPO (Invitrogen), according to the manufacturer’s instructions.
Cell transfection
For transient transfection experiments, HEK-293 cells were
cultured at 60% confluence in 6-well plates. Then, the cells were
transfected or not with the indicated vector using Transfectin (Bio-
Rad Laboratories, Inc). Transfectin and DNA were mixed in
OPTI-MEMH (GibcoH, Invitrogen) at a ratio 1.5 to 1. 24 hours
later, cells were mock- or VZV-infected and harvested at the
indicated periods of time.
siRNA transfection
siRNA directed against TBK1 was synthesized by Eurogentec
(Belgium) and the following sense sequence was used: 59-CUCUUG-
GUAUGAAGAAAUU-39. The Firefly Luciferase (GL2) siRNA
(#4627, Ambion) was used as negative control. HEK-293 cells were
seeded in 6-well plates and transfected with 100 pmol of the siRNA
using the ProFection Mammalian Transfection System – Calcium
Phosphate (#E1200, Promega) according to the manufacturer’s
instruction. After 24 hours, cells were non-infected, mock-infected or
infected with the WT VZV. Twenty four hours post-infection, cells
were harvested and IRF3 up-shift was monitored by SDS-PAGE.
TBK1 knockdown was confirmed by Western Blotting.
Lambda (l) phosphatase treatment
l-phosphatase was purchased from Westburg (#P0753). 40 mg
of total cell extracts were incubated with 400 units of l-
Phosphatase in Reaction Buffer supplemented with MnCl2 at
30uC for 45 min. Dephosphorylated protein extracts were then
incubated with SDS-loading buffer, boiled for two minutes and
resolved by SDS-PAGE.
Antibodies
The following antibodies were used in immunoblotting studies:
anti-IRF3 (#550428, BD Biosciences, Belgium), anti-TBK1 (#IMG-
270A, Imgenex-Bio-Connect BV, Netherlands), anti-TBK1 (#3013,
Cell Signaling-Bioke ´, Netherlands), anti-HSP60 (#SPA-806, Stress-
gen-Gentaur Molecular Products, Belgium), anti-HA (#MMS-101R,
Covance Europe), anti-b-actin (#A4700, Sigma, Bornem, Belgium).
VZV anti-IE63 antibody (9D12) and anti-gE (VL8) have been
described previously [61,62]. VZV anti-ORF29p antibody was
kindly provided by R. J. Cohrs. HRP secondary antibodies were
obtained from Dako N. V. (Heverlee, Belgium).
Western Blotting
Protein samples were incubated with sodium dodecylsulfate
(SDS)-loading buffer (10 mM Tris-HCl pH 6.8; 1% SDS; 25%
glycerol; 0,1 mM b-Mercaptoethanol, 0,03% bromophenol blue)
and boiled for 2 min. Proteins were then separated by SDS-PAGE
and transferred onto a polyvinylidene fluoride (PVDF) membrane
(Roche Applied Sciences, Basel, Switzerland). The membrane was
blocked with PBS-Tween containing 5% of non fat dry milk and
then incubated with the indicated antibodies. The membrane has
been developed using the Amersham ECL
TM Western Blotting
Detection Reagents Kit (GE Healthcare UK, Buckinghamshire
United Kingdom). Quantification was achieved by quantifying the
densities of the bands obtained by Western Blotting, using the
program Quantity One (Bio-Rad Laboratories Inc.).
Co-immunoprecipitation experiments
HEK-293 cells were transfected either with HA-tagged ORF47
or V5-tagged IRF3 or co-transfected with both plasmids. 24 hours
later, cells were infected or not with VZV ROka47S for another
24 hours. Cells were collected and total lysates were performed as
described previously [40]. Either IRF3 or HA-ORF47 was
immunoprecipitated from total extracts with anti-IRF3 (#sc-
9082, Tebu-bio) and anti-HA (#MMS-101R, Covance Europe)
antibodies overnight at 4uC. Immune complexes were then
incubated during 2 hours at 4uC on a rotator with 30 mlo f
washed protein A-Agarose beads (Pierce, USA). Immunoprecip-
itates were collected by centrifugation and washed five times in
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itates were then eluted in SDS 2% at 37uC for 10 min, boiled in
SDS-loading buffer and loaded on SDS-PAGE. Samples were
transferred onto a PVDF membrane. The membrane was then
blocked in PBS-tween containing 5% of non-fat dry milk and
blotted with anti-IRF3 (#550428, BD Biosciences, Belgium) and
anti-HA (#MMS-101R, Covance Europe) antibodies.
Nuclear extraction
Cells were washed with PBS and collected by scraping and
centrifuged at 200006g for 30 sec. Nuclear and cytoplasmic
fractionations were separated as described previously [63]. Briefly,
nuclei were lysed using cellular extract buffer (50 mM Tris
pH 8.0; 280 mM NaCl; 0.5% IGEPAL; 0.2 mM EDTA; 2 mM
EGTA; 10% glycerol; 1 mM DTT; 25 mM bglycerophosphate;
1 mM NaF; 1 mM Na3VO4; 1 mM PMSF; Complete
TM
(Roche)). Nuclear proteins were then used either in electrophoretic
mobility shift assay or in Western Blotting.
Native PAGE
Cells were washed with PBS and collected by scraping and
centrifuged at 200006g for 30 sec. Total proteins extracts were
performed in 75 mM NaCl; 50 mM Tris-HCl pH 7.5; 1 mM
EDTA; 1% NP-40; 1 mM DTT; 25 mM bglycerophosphate;
1 mM NaF; 1 mM Na3VO4; 1 mM PMSF; Complete
TM.
Samples were prepared in the native PAGE buffer (62.5 mM
Tris-HCl pH 6.8; 0.5% NaDeoxycholate; 15% glycerol; 0.03%
bromophenol blue) and loaded on a Ready Gel 4–15% Tris-HCl
(Bio-Rad Laboratories Inc) and run as described previously [45].
Proteins were then transferred onto a PVDF membrane. The
membrane was blocked with PBS-Tween containing 5% of non fat
dry milk and incubated with anti-IRF3 antibody.
In vitro Kinase Assay
Cells were washed, collected and subjected to a total cell lysis in
25 mM Hepes-KOH pH 7.5; 150 mM NaCl; 0.5% Triton X-100;
1 mM DTT; 25 mM bglycerolphosphate; 1 mM Na3VO4;C o m -
plete
TM.9 0 0mg of total proteins were incubated in the immunopre-
cipitation buffer (25 mMHepes-KOH pH 7.5; 150 mMNaCl;0.5%
Triton X-100; 1 mM DTT; 25 mM bglycerophosphate; 1 mM
Na3VO4;C o m p l e t e
TM)w i t h5ml of anti-TBK1 antibody (#3013,
Cell Signaling-Bioke ´) overnight at 4uC on a rotator. Immune
complexes were then incubated during 2 hours at 4uC on a rotator
with 30 ml of washed protein A-Agarose beads (Pierce, USA).
Immunoprecipitates were collected by centrifugation, washed three
times in the immunoprecipitation buffer and two times in the kinase
buffer (25 mM Hepes-KOH pH 7.5; 10 mM MgCl2; 1 mM DTT;
25 mM bglycerophosphate; 1 mM DTT; 1 mM Na3VO4). Immu-
noprecipitates were then incubated in 10 ml of kinase buffer
supplemented with 1 ml( 1 0mCi, 37610
7 mBq/mmol) of [c-
32P]
ATP (PerkinElmer, Belgium) and 1 mg of GST-IRF3 bearing the
Carboxy-end of IRF3 at 30uC for 30 min. The reaction was stopped
by the addition of 10 ml of SDS loading buffer. Proteins were boiled
for2 minandseparatedbySDS-PAGE.Thegelwastransferredonto
a PVDF membrane and exposed to Fuji X-ray films at 280uC. The
membrane was then blocked in PBS-tween containing 5% of non-fat
dry milk and immunoblotted with TBK1 antibody (#IMG-270A,
Imgenex-Bio-Connect).
Quantitative Real Time-PCR
Total RNA was isolated from cells using TriPure Isolation
Reagent (Roche, Mannheim, Germany) according to the manu-
facturer’s instructions. The reverse transcription was performed
with 1 mg of total RNA incubated one hour at 37uCi n1 5mlo f
First Strand Buffer (Invitrogen, Merelbeke, Belgium); 10 mM
dNTP (Invitrogen); 50 U RNaseOUT
TM (Invitrogen); 10 mM
DTT (Invitrogen); 0,1 mg/ml Random Primers (Invitrogen) and
250 U M-MLV Reverse Transcriptase (Invitrogen). Two micro-
liters of cDNA were then subjected to quantitative PCR in ABI
Prism 7000 sequence detection system (Applied Biosystems,
Warington, United Kingdom), using the SYBR green mix
(Applied Biosystems). The following primers were used: ikba FW
(59-CCAACCAGCCAGAAATTGCT-39), RV (59-TCTCGGAG-
CTCAGGATCACA-39); isg15 FW (59-CATCTTTGCCAGTA-
CAGGAGCT-39), RV (59-ACACCTGGAATTCGTTGCC-39);
18S FW (59-AACTTTCGATGGTAGTCGCCG-39), RV (59-
CCTTGGATGTGGTAGCCGTTT-39) (Eurogentec, Belgium).
Primers used for ifn-b were described previously [64]. Experiments
were done at least in triplicate. Differences (n-fold) between
samples were calculated using the standard-curve method and the
2-DCt method [65]. P-values were calculated using the Graphpad
Quickcalcs software (t test, www.graphpad.com). P-value ,0.05,
statistically different; P-value .0.05 not statistically different.
Electrophoretic Mobility Shift Assay
For NF-kB binding assays, a probe carrying the kB site of the
human immunodeficiency virus (HIV) long terminal repeat (LTR)
promoter was used. The gel shift experiment was performed as
described previously [50]. The gel was vacuum dried and exposed
to Fuji X-ray films overnight at 280uC.
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